New-Gen Glycopeptide Antibiotics to Tackle Resistance, with Mechanistic Insights

Paramita Sarkar

$80.95 $69.01

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Mohammed Abdul Sattar
29 March 2024

Diseases & disorders; Infectious & contagious diseases

Summary
Details

Bacterial infections are common, yet deadly, causing various chronic diseases such as diarrhoea, pneumonia and other respiratory infections, endocarditis, skin and soft tissue infections, sepsis etc. With the prevalence of antimicrobial resistance (AMR) rising, treatment of infections caused by drug-resistant pathogens has become more difficult. AMR poses such a serious problem that the World Health Organization (WHO) has declared it as one of the greatest threats to human health. Multidrug-resistant infections are either hospital-acquired or community acquired, and currently claim around 700,000 lives per annum. In developed countries like the US, about 2.8 million people suffer from drug-resistant infections resulting in nearly 35000 deaths annually.

Antimicrobial resistance is very often reported in some of the most common human pathogens like Staphylococcus aureus, Enterococcus sp., Enterobacteriaceae such as Salmonella spp., Klebsiella spp., Escherichia spp., Pseudomonas spp. and Acinetobacter spp. Gram-negative bacteria like Klebsiella spp., Escherichia spp., Pseudomonas spp. and Acinetobacter spp., which are more difficult to treat, appear to have become more invincible with the emergence of the numerous metallo-β-lactamases (MBLs) such as New-Delhi metallo-β-lactamases (NDM-I-I4), Verona-integron-borne MBLs (VIM) and Imipenemases (IMP).

various phases of clinical trials. Among these, 32 antibiotics are effective against the priority pathogens listed by WHO, 12 against Mycobacterium tuberculosis and 6 against Clostridioides difficile. 10 of these products are biological treatments that target Staphylococcus aureus, Pseudomonas aeruginosa and C. difficile. With such a limited clinical pipeline, new antibacterial agents are urgently required to keep up with the increasing prevalence of drug-resistant pathogens.

By: Paramita Sarkar
Imprint: Mohammed Abdul Sattar
Dimensions: Height: 279mm, Width: 216mm, Spine: 13mm
Weight: 590g
ISBN: 9798224812806
Pages: 250
Publication Date: 29 March 2024
Audience: General/trade , ELT Advanced
Format: Paperback
Publisher's Status: Active

PERHAPS A GIFT VOUCHER FOR MUM?: MOTHER'S DAY

New-Gen Glycopeptide Antibiotics to Tackle Resistance, with Mechanistic Insights

Paramita Sarkar

$80.95 $69.01

Paperback

See Also

Contact Abbeys

Contact Galaxy

Contact Language

Contact Us

About ABBEY'S